Recombinant Human PD-L1 (C-mFc)

Description

EnkiLife provides the Recombinant Human PD-L1 (C-mFc) protein,aslo know as Programmed Cell Death 1 Ligand 1,PD-L1,PDCD1 Ligand 1,Programmed Death Ligand 1,B7 Homolog 1,B7-H1,CD274,B7H1,PDCD1L1,PDCD1LG1,PDL1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Programmed Cell Death 1 Ligand 1 is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:Q9NZQ7. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:50.9 KDa. Background:CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.